Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 224

The DOI matches its Crossref record.

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

Open access
Avet-Loiseau, Hervé, Attal, Michel, Campion, Loic, Caillot, Denis, Hulin, Cyrille, Marit, Gerald, Stoppa, Anne-Marie, Voillat, Laurent, Wetterwald, Marc, Pegourie, Brigitte, Voog, Eric, Tiab, Mourad, Banos, Anne, Jaubert, Jerome, Bouscary, Didier, Macro, Margaret, Kolb, Brigitte, Traulle, Catherine, Mathiot, Claire, Magrangeas, Florence, Minvielle, Stephane, Facon, Thierry, Moreau, Philippe · 2012 · Journal of Clinical Oncology

Abstract

Purpose: In multiple myeloma, many prognostic parameters have been proposed. However, all of these predict shorter survival. To identify patients with a longer life expectancy, we updated the data of patients treated in the IFM (Intergroupe Francophone du Myelome) 99-02 and 99-04 trials. Patients and Methods: A series of 520 patients was analyzed. Median follow-up was 90.5 months. To perform a comprehensive analysis of the major prognostic factors, we reanalyzed all patients for 1q gains [in addition to updating del(13), t(4;14), and del(17p) analyses]. Results: It was possible to identify a subgroup of patients (representing 20% of total patients) with an 8-year survival of 75%. These patients were defined by the absence of t(4;14), del(17p), and 1q gain and β 2-microglobulin less than 5.5 mg/L. Conclusion: We propose that all patients with newly diagnosed multiple myeloma be evaluated for these three chromosomal changes, not only to define high-risk patients but also to identify those with a longer life expectancy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.36.5726

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 224

Metadata

Authors
Avet-Loiseau, H., Attal, M., Campion, L., Caillot, D., Hulin, C., Marit, G., Stoppa, A.-M., Voillat, L., Wetterwald, M., Pegourie, B., Voog, E., Tiab, M., Banos, A., Jaubert, J., Bouscary, D., Macro, M., Kolb, B., Traulle, C., Mathiot, C., Magrangeas, F., Minvielle, S., Facon, T., & Moreau, P.
Venue
Journal of Clinical Oncology
Published
2012-06-01
Volume
30
Issue
16
Pages
1949-1952
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2131837746
Cited by
224
References
0
FWCI
14.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival. https://app.cochat.ai/papers/10.1200/jco.2011.36.5726
The paper
Avet-Loiseau, H., Attal, M., Campion, L., Caillot, D., Hulin, C., Marit, G., Stoppa, A.-M., Voillat, L., Wetterwald, M., Pegourie, B., Voog, E., Tiab, M., Banos, A., Jaubert, J., Bouscary, D., Macro, M., Kolb, B., Traulle, C., Mathiot, C., . . . Moreau, P. (2012). Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.36.5726

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.